Lifesaving vaccine against Menningitis B to be licensed

A lifesaving vaccine against Meningitis B is set to be licensed for use in the UK in a move that could save thousands of lives.

The disease, which is the most common and deadliest form of meningitis in the country, affects an average of 1,870 people a year, many of them children, and results in death for one in 10 sufferers.

The approval of the new 4CMenB vaccine, which is developed by pharmaceutical company Novartis, has been hailed as the "biggest leap forward in the field in the three decades" by the charity Meningitis UK.